No abstract

Background: Coronavirus disease-2019 (COVID-19) is a global pandemic health problem which causes a wide spectrum of clinical manifestations and considerable mortality rates. Unfortunately, recovered patients who survive COVID-19 may continue to report wide varieties of clinical manifestations of multisystem affection such as fatigue, dyspnea, myalgia, anxiety, depression, acute myocardial infarction, peripheral and pulmonary embolisms. Objective: We aimed to assess the prevalence of post-COVID-19 manifestations. Methods: We conducted a systematic review on post COVID-19 manifestations by searching Pubmed, Scopus, Web of Science (WOS), EBSCO, Wily, and World health organization (WHO) databases. Screening, selection, data extraction, data synthesis and quality assessment were done by two independent reviewers. Results: Of 1,371 references, 817 references remained after duplicates, reviews; case reports, commentaries, and any article containing non-original information were removed. According to eligibility criteria for this systematic review, 12 studies were included for qualitative synthesis. The overall prevalence of post-COVID-19 manifestations ranged from 35% to 90.5%. Fatigue, dyspnea, neuropsychological disorders, and pain were the most frequent post COVID-19 symptoms. Conclusion: This systematic review showed that 35% to 90.5% of recovered patients who survive COVID-19 continue to have wide varieties of clinical manifestations and fatigue, dyspnea, neuropsychological disorders, and pain were the most frequent post COVID-19 symptoms.

An informed written consent has been obtained from all included patients and the study protocol was approved by ethical committee and institutional review board

Background Since the emergence of the novel corona virus (SARS-Cov-2) in the late 2019 and not only the endoscopy practice and training but also the health care systems around the globe suffers. This systematic review focused the impact of Corona Virus Disease (COVID-19) on the endoscopy practice. Methods A web search of different databases combining different search terms describing the endoscopy practice and the COVID-19 pandemic was done. Articles were screened for selection of relevant articles in two steps: title and abstract step and full-text screening step, by two independent reviewers and any debate was solved by a third reviewer. Results Final studies included in qualitative synthesis were 47. The data shown in the relevant articles were evident for marked reduction in the volume of endoscopy, marked affection of colorectal cancer screening, impairments in the workflow, deficiency in personal protective equipment (PPE) and increased likelihood of catching the infection among both the staff and the patients. Conclusion The main outcomes from this review are rescheduling of endoscopy procedures to be suitable with the situation of COVID-19 pandemic in each Country. Also, the endorsement of the importance of PPE use for health care workers and screening of COVID-19 infection pre-procedure. Key messages The data focussing Gastrointestinal Endoscopy and COVID-19 emerged from different areas around the globe. The data presented on the published studies were heterogeneous. However, there were remarkable reductions in the volume of GI endoscopy worldwide Staff reallocation added a burden to endoscopy practice There was a real risk for COVID-19 spread among both the staff and the patients

Infection with the hepatitis C virus (HCV) is a global health concern, with an estimated 71 million people infected in 2015 and 400 000 deaths each year. [1][2][3][4][5][6][7][8][9][10] HCV is the leading cause of liver disease, and there is currently no vaccination available to protect against it. Drugs known as direct-acting antivirals (DAAs) have now been approved for children as young as 3 years old. HCV elimination techniques for children, on the other hand, have yet to be developed. [10][11][12][13][14][15][16][17][18][19][20][21] Estimates of paediatric prevalence are needed to aid in the scaling up of therapy and screening and testing approaches for this population. The prevalence of HCV in this unique community has not been adequately investigated. [2][3][4][5][6][7][8][9] In Western Europe, the prevalence is expected to be 1.5% to 3.5%, but barely 0.5% in the United Kingdom, with little information on the prevalence in low-income countries. [2][3][4][5][6][7][8][9][10] HCV infection raises the risk of morbidity and mortality, and it is the major cause of end-stage liver disease, cirrhosis and liver cancer in people all over the world. [18][19][20][21][22][23] Despite the fact that HCV infection seldom causes morbidity in children, the majority of HCV-infected children develop chronic HCV, putting them at risk for life-threatening liver disease. [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] Furthermore, some research suggests that HCV has an impact on children's quality of life and behaviour, as cognitive function has been proven to be impaired, and families have reported greater levels of stress, both of which have a negative impact on family connections and well-being. [21][22][23][24][25][26][27] There are few statistics on the prevalence of HCV in children at the moment. [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] The purpose of this study was to look at